May 3, 2024, 2:44 PM
May 1, 2024, 11:04 AM

Amgen CEO Provides Promising Update on Experimental Weight Loss Drug

Highlights
  • Amgen's CEO gives an encouraging update on the experimental weight loss drug MariTide.
  • Investors are eager for the Phase 2 trial data expected later this year.
  • Amgen's move to focus on injection over a pill signals competition in the weight loss drug market.

Opinions

You've reached the end